Hyperaldosteronism

Hyperaldosteronism (Primary Aldosteronism) – High‑Yield Study Guide

Definition

Hyperaldosteronism refers to a clinical state of inappropriately increased aldosterone activity leading to sodium retention, potassium wasting, and suppression of renin. In clinical practice, the key entity is primary aldosteronism (PA), in which autonomous aldosterone production from the adrenal cortex occurs independently of renin–angiotensin signaling. This is distinct from secondary hyperaldosteronism, where aldosterone elevation is driven by increased renin (e.g., renal artery stenosis, diuretic use, heart failure). Primary aldosteronism is now recognized as the most common cause of endocrine secondary hypertension and exists along a spectrum from subclinical to overt disease.^[1]

Epidemiology

Historically considered rare, primary aldosteronism is now known to account for approximately 5–10% of all hypertension cases in specialty clinics, and an even higher proportion among patients with resistant or severe hypertension.^[1] It is an important, potentially curable subtype of endocrine hypertension, which itself represents a small but clinically significant subset of secondary hypertension with high cardiovascular risk.^[2]

Primary aldosteronism is frequently underdiagnosed in hospitalized and outpatient populations, with studies showing low rates of formal testing in eligible hypertensive patients.^[3] PA is overrepresented among individuals with premature cardiovascular disease, including premature coronary artery disease and stroke, underscoring the need for early detection.^[4]

Pathophysiology

Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex and acts mainly on the distal nephron to increase sodium reabsorption and potassium and hydrogen ion excretion. In primary aldosteronism, autonomous aldosterone production leads to:

• Renal sodium and water retention → expansion of extracellular volume and hypertension.
• Renal potassium wasting → hypokalemia, which can cause muscle weakness and arrhythmias.
• Suppression of renin due to volume expansion, leading to a low renin state despite hypertension.

Mechanistically, PA is most commonly due to either:

• Aldosterone-producing adenoma (APA): Unilateral benign adrenal cortical tumor that secretes aldosterone autonomously.
• Bilateral adrenal hyperplasia (BAH) or idiopathic hyperaldosteronism: Bilateral zona glomerulosa hyperplasia with diffuse or nodular changes and autonomous aldosterone production.

Two major subtypes, APA and bilateral idiopathic hyperaldosteronism, demonstrate differences in aldosterone responsiveness to adrenocorticotropic hormone (ACTH), suggesting heterogeneity in steroidogenic regulation at the cellular level.^[5]

Chronically, aldosterone exerts non-hemodynamic effects on the myocardium, vasculature, and kidneys, including fibrosis, endothelial dysfunction, and inflammation, explaining the disproportionate cardiometabolic risk (e.g., atrial fibrillation, left ventricular hypertrophy, stroke, and CKD) compared with blood pressure–matched essential hypertension.^[1]

Clinical Presentation

The clinical spectrum ranges from asymptomatic or normokalemic hypertension to classic hypokalemic presentations. Many patients have subtle or nonspecific symptoms.

• Hypertension
  • Often moderate to severe; may be resistant to ≥3 antihypertensive agents (including a diuretic).
  • May present as early-onset or difficult-to-control hypertension.
• Electrolyte abnormalities
  • Hypokalemia (spontaneous or diuretic-induced) is classic but not universal; many patients are normokalemic.
  • Metabolic alkalosis due to H⁺ loss.
• Symptoms of hypokalemia
  • Muscle weakness, fatigue, cramps.
  • Palpitations or arrhythmias in severe hypokalemia.
  • Polyuria and polydipsia (from nephrogenic concentrating defect).
• Cardiometabolic manifestations
  • Left ventricular hypertrophy, heart failure, atrial fibrillation.
  • Increased risk of stroke, coronary artery disease, and CKD independent of blood pressure levels.^[1]
  • Reports of severe hypertension–related complications such as aortic dissection in the setting of untreated PA.^[6]
• Associations
  • May coexist with other adrenal-related endocrine disorders and comorbidities (e.g., Cushing syndrome, pheochromocytoma) in rare cases.^[7]

Diagnosis

Diagnosis involves a structured approach: screening, confirmatory testing, subtype classification, and assessment for complications.

Who to Screen

Current endocrine and hypertension guidelines recommend screening for primary aldosteronism in high-risk groups, including:

• Resistant hypertension (uncontrolled on ≥3 drugs or controlled on ≥4).
• Hypertension with spontaneous or diuretic-induced hypokalemia.
• Hypertension with adrenal incidentaloma.
• Early-onset hypertension or strong family history of early cardiovascular disease.
• Hypertension with obstructive sleep apnea or disproportionate target-organ damage.

Screening: Aldosterone–Renin Ratio (ARR)

The primary screening test is the aldosterone–renin ratio (ARR).^[1]

• Measure plasma aldosterone concentration (PAC) and plasma renin (activity or concentration) in the morning after patient has been ambulatory; correct significant hypokalemia before testing.
• Interpretation: Elevated PAC with suppressed renin and an increased ARR suggests primary aldosteronism. Exact cutoffs vary by assay and guideline, but typically ARR is elevated when PAC is ≥10–15 ng/dL with renin suppressed.
• Medications such as mineralocorticoid receptor antagonists, high-dose diuretics, and beta-blockers can interfere and may need adjustment prior to testing when feasible.

Confirmatory Testing

If the ARR is positive, confirmatory tests are used to demonstrate autonomous aldosterone production (lack of suppressibility). Commonly used protocols include:^[1]

• Saline infusion test: 2 L of isotonic saline IV over 4 hours; failure of PAC to suppress below a defined threshold supports PA.
• Oral sodium loading test: High-salt diet for 3 days followed by 24-hour urinary aldosterone measurement.
• Captopril challenge test: Measurement of PAC and renin before and after captopril; persistent high aldosterone with suppressed renin supports PA.

In patients with very high PAC, suppressed renin, and spontaneous hypokalemia, some guidelines allow bypassing formal confirmatory testing.

Subtype Classification

Once primary aldosteronism is biochemically confirmed, the next step is distinguishing unilateral (e.g., APA, unilateral hyperplasia) from bilateral disease (e.g., idiopathic hyperaldosteronism) to guide therapy.

• Imaging
  • Adrenal CT or MRI is used to identify adenomas, carcinomas, or nodular hyperplasia and to exclude large or suspicious masses.
  • However, imaging alone cannot reliably distinguish functional from nonfunctional adrenal nodules, especially in older patients.
• Adrenal vein sampling (AVS)
  • Gold standard for lateralization, comparing aldosterone-to-cortisol ratios from right and left adrenal veins.
  • Indicated in most surgical candidates to differentiate unilateral from bilateral secretion.
  • Some young patients (<35 years) with marked biochemical PA and a clear unilateral adenoma on CT may proceed directly to surgery in selected centers.

Management

Management aims to normalize blood pressure, correct hypokalemia, and reduce long-term cardiovascular and renal risk. Treatment strategy depends on whether disease is unilateral or bilateral.

Medical Therapy

Mineralocorticoid receptor antagonists (MRAs) are the cornerstone of medical therapy, especially in bilateral disease or when surgery is not feasible.

• Spironolactone
  • Non-selective MRA that reduces aldosterone-mediated sodium retention and potassium wasting, improving blood pressure and cardiovascular outcomes in PA and other conditions such as HFrEF.^[8]
  • Usual dosing in PA: often started around 12.5–25 mg daily and titrated up (e.g., 50–100 mg/day or higher as needed and tolerated).
  • Adverse effects: gynecomastia, menstrual irregularities, decreased libido, hyperkalemia, and renal dysfunction.
• Eplerenone
  • More selective MRA with fewer sex hormone–related side effects; also effective in lowering BP and mitigating aldosterone effects.^[8]
  • Requires twice-daily dosing and may be less potent; useful when spironolactone is poorly tolerated.
• Other agents
  • Amiloride (ENaC blocker) can be used as adjunct or alternative, particularly in those who cannot tolerate MRAs.
  • Standard antihypertensive agents (ACE inhibitors, ARBs, CCBs, thiazides) are often used in combination to control blood pressure.

Careful monitoring of serum potassium and renal function is required during MRA therapy.

Surgical Management

Unilateral laparoscopic adrenalectomy is the treatment of choice for unilateral aldosterone-producing adenomas or unilateral hyperplasia. Minimally invasive approaches (total or partial adrenalectomy) have shown favorable long-term outcomes in selected patients.^[9]

• Outcomes
  • High rates of biochemical cure (normalization of aldosterone, potassium, and renin).
  • Many patients experience improvement or cure of hypertension; a subset may still require antihypertensives.
  • Surgery can reduce long-term risks of cardiovascular events and CKD compared with ongoing medical therapy alone in appropriate candidates.
• Partial vs total adrenalectomy
  • Partial adrenalectomy (MIPA) aims to preserve adrenal tissue while removing functional adenoma; compared with total adrenalectomy (MITA), both have shown good long-term control when carefully selected.^[9]
  • The choice is individualized based on lesion size, location, and surgical expertise.

Postoperatively, patients require monitoring for transient hypoaldosteronism, hypotension, hyperkalemia, and need for adjustment of antihypertensives.

Monitoring and Long-Term Management

• Regular blood pressure and electrolyte monitoring (K⁺, Na⁺).
• Renal function assessment, as long-standing PA and aggressive diuresis/MRA therapy can impact GFR.
• Assessment and management of cardiometabolic comorbidities (AF, LVH, CAD, diabetes, dyslipidemia).^[1]
• In younger patients or those with family history, consider evaluation for familial hyperaldosteronism subtypes.

Key Clinical Pearls

• Most common endocrine cause of secondary hypertension: Primary aldosteronism is far more prevalent than previously believed, particularly in resistant or severe hypertension.^[1]
• Hypokalemia is not mandatory: Many patients with PA are normokalemic; relying solely on hypokalemia misses a large proportion of cases.^[1]
• Screen high-risk groups: Resistant hypertension, early-onset hypertension, adrenal incidentaloma, or disproportionate end-organ damage should prompt ARR screening.
• ARR is the key screening tool: Elevated aldosterone with suppressed renin and a high ARR strongly suggests PA and warrants confirmatory testing.
• Subtype classification guides therapy: Unilateral disease is potentially curable with surgery; bilateral disease is best managed with MRAs.
• Cardiovascular risk is disproportionately high: PA confers greater risks of AF, stroke, CAD, and kidney disease than essential hypertension with similar BP levels, highlighting the importance of early detection and targeted therapy.^[1],[4]
• PA can contribute to severe vascular complications: Case reports describe aortic dissection and other catastrophic events in untreated hyperaldosteronism, likely due to chronic severe hypertension.^[6]
• MRAs are cornerstone therapy: Spironolactone and eplerenone not only control BP and potassium but also mitigate aldosterone-mediated organ damage.^[8]
• AI and multiomics are emerging tools: Future strategies using AI and multiomic profiling aim to enhance detection and subtype classification of endocrine hypertension, including PA.^[2]
• Think PA in premature CAD: Given its prevalence in premature coronary artery disease, consider screening in young MI or CAD patients with hypertension.^[4]

For exam purposes, focus on recognizing the classic triad of hypertension, hypokalemia, and low renin, the role of the aldosterone–renin ratio in screening, and the distinction between unilateral (surgical) and bilateral (medical) disease. Clinically, maintain a low threshold for screening in patients with resistant or early-onset hypertension, and remember that timely diagnosis and tailored treatment can significantly improve long-term cardiovascular outcomes.